Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
N Engl J Med ; 372(10): 933-43, 2015 Mar 05.
Article in English | MEDLINE | ID: mdl-25738669

ABSTRACT

BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS: We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks of therapy. The primary end point was the change in hearing in the better ear ("best-ear" hearing) from baseline to 6 months. Secondary end points included the change in hearing from baseline to follow-up at 12 and 24 months and neurodevelopmental outcomes, with each end point adjusted for central nervous system involvement at baseline. RESULTS: A total of 96 neonates underwent randomization, of whom 86 had follow-up data at 6 months that could be evaluated. Best-ear hearing at 6 months was similar in the 6-month group and the 6-week group (2 and 3 participants, respectively, had improvement; 36 and 37 had no change; and 5 and 3 had worsening; P=0.41). Total-ear hearing (hearing in one or both ears that could be evaluated) was more likely to be improved or to remain normal at 12 months in the 6-month group than in the 6-week group (73% vs. 57%, P=0.01). The benefit in total-ear hearing was maintained at 24 months (77% vs. 64%, P=0.04). At 24 months, the 6-month group, as compared with the 6-week group, had better neurodevelopmental scores on the Bayley Scales of Infant and Toddler Development, third edition, on the language-composite component (P=0.004) and on the receptive-communication scale (P=0.003). Grade 3 or 4 neutropenia occurred in 19% of the participants during the first 6 weeks. During the next 4.5 months of the study, grade 3 or 4 neutropenia occurred in 21% of the participants in the 6-month group and in 27% of those in the 6-week group (P=0.64). CONCLUSIONS: Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, did not improve hearing in the short term but appeared to improve hearing and developmental outcomes modestly in the longer term. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00466817.).


Subject(s)
Antiviral Agents/administration & dosage , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/drug therapy , Ganciclovir/analogs & derivatives , Hearing Loss, Sensorineural/prevention & control , Antiviral Agents/adverse effects , Audiometry , Child Development , Cytomegalovirus Infections/complications , Double-Blind Method , Drug Administration Schedule , Evoked Potentials, Auditory, Brain Stem , Ganciclovir/administration & dosage , Ganciclovir/adverse effects , Gestational Age , Hearing Loss, Sensorineural/virology , Humans , Infant, Newborn , Neutropenia/chemically induced , Valganciclovir
2.
Pediatr Infect Dis J ; 43(10): 977-979, 2024 Oct 01.
Article in English | MEDLINE | ID: mdl-38865503

ABSTRACT

BACKGROUND: Testing for syphilis and HIV is indicated in prenatal care in the United States. Effective antiretroviral therapy during pregnancy reduces mother-to-child HIV transmission (MTCT) to less than 1%. Syphilis infection in pregnant women with unsuppressed HIV increases the risk of MTCT, usually in utero. The incidences of syphilis in women of childbearing age and corresponding congenital syphilis are increasing in the United States. METHODS: We report 3 cases of in utero HIV transmission associated with maternal syphilis that occurred during the ongoing syphilis epidemic. RESULTS: All 3 women had untreated HIV infection and active syphilis with placentitis during late pregnancy. Their newborns were found to have symptomatic congenital syphilis and HIV infection from in utero transmission. The babies' antiretroviral resistance patterns were nearly identical to their mothers'. CONCLUSIONS: When untreated syphilis and uncontrolled HIV coincide in pregnancy, there is a high likelihood of in utero mother-to-child HIV transmission. The current syphilis epidemic in the United States may lead to an increase in MTCT.


Subject(s)
HIV Infections , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious , Syphilis , Humans , Pregnancy , Female , HIV Infections/transmission , HIV Infections/drug therapy , Pregnancy Complications, Infectious/drug therapy , Syphilis/transmission , Syphilis/epidemiology , Syphilis/drug therapy , Infant, Newborn , Adult , United States/epidemiology , Drug Resistance, Viral , Pandemics , Syphilis, Congenital/transmission
3.
Article in English | MEDLINE | ID: mdl-36833690

ABSTRACT

Though Hispanic youth with perinatally acquired HIV (PHIV) comprise 14% of those living with PHIV, little research has documented their lived experiences. Eighteen Hispanic adolescents and young adults (AYA) with PHIV were recruited from two pediatric infectious disease clinics in California (mean age = 20.8 years, 12 females and 6 males). Interview transcripts were analyzed for emergent themes regarding relationships, childbearing intentions, and future career aspirations. Participants acknowledged HIV as cause for rejection and fear of transmission from partners. Most desired children in the future. Those with children (n = 7) expressed a strong desire to continue their education for the benefit of their children. Many did not view HIV as a barrier to their career aspirations. HIV influenced their daily lives. However, the challenges of poverty, loss, and trauma also significantly shaped their well-being. Health care providers offered emotional and instrumental support which helped AYA make progress towards their goals.


Subject(s)
HIV Infections , Adolescent , Female , Humans , Male , Young Adult , Hispanic or Latino , HIV Infections/psychology , Infectious Disease Transmission, Vertical , Poverty
4.
Clin Infect Dis ; 55(6): 877-84, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22675157

ABSTRACT

BACKGROUND: Before highly active antiretroviral therapy (HAART), congenital cytomegalovirus (CMV) rates were higher among human immunodeficiency virus (HIV)-exposed infants than unexposed infants. This study examines congenital and perinatal/early postnatal (P/EP) CMV among HIV-exposed infants pre- and post- HAART. METHODS: Infants born to HIV-infected women were evaluated for congenital CMV (CMV-positive culture in first 3 weeks of life) and P/EP CMV (positive culture in first 6 months of life). Prenatal maternal HAART was defined as triple antiretroviral therapy (ART) with at least 1 nonnucleoside reverse-transcriptase inhibitor or protease inhibitor. RESULTS: Among 414 infants evaluated, 1678 CMV assessment days were completed (mean = 3 assessment days per infant). Congenital CMV rates did not differ by time period, HAART use, or infant HIV infection status. P/EP CMV rates were greater for the 1988-1996 birth cohort (17.9%) compared with the 1997-2002 birth cohort (8.9%) (P < .01), HIV-infected versus uninfected infants (P < .01), and infants with no maternal ART versus those with ART (P < .01). Controlling for potential confounders, P/EP CMV was associated with no maternal ART (odds ratio = 4.7; P < .01), and among those with no maternal ART, P/EP CMV was associated with maternal CD4 count ≤200 cells/µL (P < .01). For HIV-uninfected infants with P/EP CMV, symptoms including splenomegaly, lymphadenopathy, and hepatomegaly were associated with no maternal HAART versus those with HAART (41% vs 6%; P < .05). CONCLUSIONS: Although congenital CMV rates did not change, the post-HAART era showed reduced P/EP CMV and occurrence of related clinical symptoms. These findings underscore the importance of prenatal HAART for all HIV-infected pregnant women.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/transmission , HIV Infections/drug therapy , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/drug therapy , Adult , Cytomegalovirus/isolation & purification , Female , Humans , Infant , Infant, Newborn , Male , Pregnancy , Prevalence , Virus Cultivation
5.
J Child Neurol ; 37(4): 268-272, 2022 03.
Article in English | MEDLINE | ID: mdl-35014889

ABSTRACT

Similar to the pathogenesis of autoimmune disease, SARS-CoV-2 (COVID-19) infection has been shown to be associated with dysregulated and persistent inflammatory reactions and production of some antibodies. We report 3 pediatric patients found to have serum SARS-CoV-2 antibodies who presented with neurologic findings suggestive of postinfectious autoimmune-mediated encephalitis. All 3 cases showed lymphocytic pleocytosis on cerebrospinal fluid studies and marked improvement in neurologic symptoms after high-dose intravenous corticosteroids. The manifestations of SARS-CoV-2 infection in the pediatric population are still an evolving area of study, and these cases suggest autoimmune-mediated encephalitis as yet another SARS-CoV-2 related complication.


Subject(s)
COVID-19 , Encephalitis , Hashimoto Disease , COVID-19/complications , Child , Encephalitis/complications , Encephalitis/etiology , Humans , SARS-CoV-2
6.
Clin Infect Dis ; 53(12): 1252-4, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21987729

ABSTRACT

Coccidioidal meningitis is a potentially lethal infection. Disease progression while taking fluconazole is a common complication and safe, effective, alternative treatments are limited. Posaconazole therapy resulted in symptomatic and laboratory improvement in 2 patients and clinical improvement in a third patient with chronic, previously unresponsive coccidioidal meningitis.


Subject(s)
Antifungal Agents/administration & dosage , Coccidioides/isolation & purification , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Meningitis, Fungal/diagnosis , Meningitis, Fungal/drug therapy , Triazoles/administration & dosage , Adolescent , Adult , Chronic Disease/therapy , Coccidioidomycosis/microbiology , Coccidioidomycosis/pathology , Humans , Male , Meningitis, Fungal/microbiology , Meningitis, Fungal/pathology , Treatment Outcome , Young Adult
7.
AIDS ; 35(3): 419-427, 2021 03 01.
Article in English | MEDLINE | ID: mdl-33252481

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate safety and pharmacokinetics of maraviroc administered with standard antiretroviral prophylaxis to HIV-1 exposed infants and to determine the appropriate dose of maraviroc during the first 6 weeks of life. DESIGN: A phase I, multicentre, open-label study enrolling two sequential cohorts. METHODS: IMPAACT 2007 participants enrolled by day 3 of life and were stratified by exposure to maternal efavirenz. Cohort 1 participants received two single 8 mg/kg maraviroc doses 1 week apart with pharmacokinetic sampling after each dose. Cohort 2 participants received 8 mg/kg maraviroc twice daily through 6 weeks of life with pharmacokinetic sampling at weeks 1 and 4. Maraviroc exposure target was Cavg at least 75 ng/ml. Laboratory and clinical evaluations assessed safety. RESULTS: Fifteen Cohort 1 and 32 Cohort 2 HIV-exposed neonates were enrolled (median gestational age 39 weeks, 51% male). All 13 evaluable Cohort 1 infants met the pharmacokinetic target. Median exposure for the 25 evaluable Cohort 2 infants met the pharmacokinetic target but variability was high, with 17-33% of infants below target at Weeks 1 and 4. Pharmacokinetic target achievement was similar between efavirenz exposure strata. No Grade 3+ toxicities, early study or treatment discontinuations due to maraviroc occurred. CONCLUSION: Median maraviroc exposure met the Cavg target in neonates receiving 8 mg/kg twice daily, although exposures were variable. Maternal efavirenz use did not impact maraviroc exposure and no discontinuations were due to maraviroc toxicity/intolerance. No infants acquired HIV-1 infection during follow-up. Maraviroc 8 mg/kg twice daily appears well tolerated during the first 6 weeks of life.


Subject(s)
HIV Infections , HIV-1 , Adult , Anti-Retroviral Agents/therapeutic use , Cohort Studies , Cyclohexanes/adverse effects , Female , HIV Infections/drug therapy , Humans , Infant, Newborn , Male , Maraviroc
8.
J Acquir Immune Defic Syndr ; 71(2): 155-62, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26334738

ABSTRACT

BACKGROUND: Plasma HIV RNA is the most significant determinant of cervical HIV shedding. However, shedding is also associated with sexually transmitted infections (STIs) and cervical inflammation. The mechanism by which this occurs is poorly understood. There is evidence that systemic immune activation promotes viral entry, replication, and HIV disease progression. We hypothesized that systemic immune activation would be associated with an increase in HIV genital shedding. METHODS: Clinical assessments, HIV RNA in plasma and genital secretions, and markers of immune activation (CD38(+)DR(+) and CD38(-)DR(-)) on CD4(+) and CD8(+) T cells in blood were evaluated in 226 HIV+ women enrolled in the Women's Interagency HIV Study. There were 569 genital evaluations of which 159 (28%) exhibited HIV RNA shedding, defined as HIV viral load >80 copies per milliliter. We tested associations between immune activation and shedding using generalized estimating equations with logit link function. RESULTS: In the univariate model, higher levels of CD4(+) and CD8(+) T-cell activation in blood were significantly associated with genital tract shedding. However, in the multivariate model adjusting for plasma HIV RNA, STIs, and genital tract infections, only higher levels of resting CD8(+) T cells (CD38(-)DR(-)) were significantly inversely associated with HIV shedding in the genital tract (odds ratios = 0.44, 95% confidence interval: 0.21 to 0.9, P = 0.02). CONCLUSIONS: The association of systemic immune activation with genital HIV shedding is multifactorial. Systemic T-cell activation is associated with genital tract shedding in univariate analysis but not when adjusting for plasma HIV RNA, STIs, and genital tract infections. In addition, women with high percentage of resting T cells are less likely to have HIV shedding compared with those with lower percentages. These findings suggest that a higher percentage of resting cells, as a result of maximal viral suppression with treatment, may decrease local genital activation, HIV shedding, and transmission.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Genitalia, Female/virology , HIV Infections/immunology , HIV-1/isolation & purification , Sexually Transmitted Diseases/immunology , Adult , Female , Genitalia, Female/immunology , HIV Infections/virology , HIV-1/genetics , Humans , Lymphocyte Activation , RNA, Viral/blood , RNA, Viral/genetics , Sexually Transmitted Diseases/microbiology , Virus Shedding
9.
Addiction ; 100(5): 626-35, 2005 May.
Article in English | MEDLINE | ID: mdl-15847620

ABSTRACT

AIMS: Vertical transmission of HCV is increased among HIV-1/HCV coinfected women and is related to HCV viral load. In this study we assessed clinical and demographic factors associated with HCV viremia in a cohort of young pregnant and non-pregnant mothers coinfected with HIV-1. DESIGN: A cross-sectional clinic-based study nested within a prospective cohort study. METHODS: From 1988 to 2000, HIV-1 + pregnant and non-pregnant women with children followed in a large maternal, child and adolescent HIV-1 clinic were evaluated for HCV infection using EIA 3.0. HCV RNA levels were determined for HCV antibody + women using polymerase chain reaction. Demographic and clinical characteristics between HCV-RNA(+) and HCV-RNA(-) women and between pregnant and non-pregnant HIV-1/HCV coinfected women were compared using univariate and multivariate analyses. FINDINGS: Among 359 HIV-1(+) women, 84 (23%) were HCV-ab + and 49/84 (58%) had detectable HCV-RNA in plasma. Median age was 31. CD4 counts, HIV-1 RNA levels and demographic characteristics were similar for viremic and non-viremic women and pregnant and non-pregnant women. However, viremic women were more likely to report a history of (88% versus 43%; P < 0.001) or active injection drug use (AIDU) (83% versus 29%; P < 0.001). Logistic regression analysis showed that HCV viremia was associated significantly with AIDU (adjusted OR: 15.17; 95% CI: 3.56, 64.56) after adjusting for age, race, number of sexual partners, pregnancy status, CD4 counts and HIV-1 viral load. CONCLUSION: In this cohort of young HIV-1 and HCV coinfected women, HCV viremia was associated strongly with active injection drug use, perhaps due to reinfection or reactivation of HCV. Thus, careful evaluation for HCV infection and counseling related to drug use may be necessary.


Subject(s)
HIV Infections/complications , Hepatitis C/transmission , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/virology , Substance Abuse, Intravenous/complications , Viremia/etiology , Adult , Cohort Studies , Cross-Sectional Studies , Female , Hepacivirus/genetics , Hepacivirus/isolation & purification , Humans , Pregnancy , Prospective Studies , Viral Load
10.
Pediatr Infect Dis J ; 21(12): 1169-71, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12506952

ABSTRACT

Skeletal muscle infection caused by Mycobacterium tuberculosis is rare and usually caused by invasion from adjacent structures. We describe a 15-year-old male youth with tuberculous right inguinal lymphadenitis and right calf swelling who had tuberculous pyomyositis of the soleus, probably resulting from hematogenous seeding. Tuberculosis should be suspected as the cause of pyomyositis, especially if present elsewhere.


Subject(s)
Muscle, Skeletal/microbiology , Mycobacterium Infections/diagnosis , Mycobacterium tuberculosis/isolation & purification , Myositis/microbiology , Adolescent , Antitubercular Agents/administration & dosage , Biopsy, Needle , Combined Modality Therapy , Drainage/methods , Follow-Up Studies , Humans , Male , Muscle, Skeletal/physiopathology , Mycobacterium Infections/therapy , Myositis/diagnosis , Myositis/therapy , Treatment Outcome
11.
J Acquir Immune Defic Syndr ; 60(1): 99-110, 2012 May 01.
Article in English | MEDLINE | ID: mdl-22517416

ABSTRACT

BACKGROUND: Cervicovaginal HIV level (CV-VL) influences HIV transmission. Plasma viral load (PVL) correlates with CV-VL, but discordance is frequent. We evaluated how PVL, behavioral, immunological, and local factors/conditions individually and collectively correlate with CV-VL. METHODS: CV-VL was measured in the cervicovaginal lavage fluid (CVL) of 481 HIV-infected women over 976 person-visits in a longitudinal cohort study. We correlated identified factors with CV-VL at individual person-visits and detectable/undetectable PVL strata by univariate and multivariate linear regression and with shedding pattern (never, intermittent, persistent ≥3 shedding visits) in 136 women with ≥3 visits by ordinal logistic regression. RESULTS: Of 959 person-visits, 450 (46.9%) with available PVL were discordant, 435 (45.3%) had detectable PVL with undetectable CV-VL, and 15 (1.6%) had undetectable PVL with detectable CV-VL. Lower CV-VL correlated with highly active antiretroviral therapy (HAART) usage (P = 0.01). Higher CV-VL correlated with higher PVL (P < 0.001), inflammation-associated cellular changes (P = 0.03), cervical ectopy (P = 0.009), exudate (P = 0.005), and trichomoniasis (P = 0.03). In multivariate analysis of the PVL-detectable stratum, increased CV-VL correlated with the same factors and friability (P = 0.05), while with undetectable PVL, decreased CV-VL correlated with HAART use (P = 0.04). In longitudinal analysis, never (40.4%) and intermittent (44.9%) shedding were most frequent. Higher frequency shedders were more likely to have higher initial PVL [odds ratio (OR) = 2.47/log10 increase], herpes simplex virus type 2 seropositivity (OR = 3.21), and alcohol use (OR = 2.20). CONCLUSIONS: Although PVL correlates strongly with CV-VL, discordance is frequent. When PVL is detectable, cervicovaginal inflammatory conditions correlate with increased shedding. However, genital shedding is sporadic and not reliably predicted by associated factors. HAART, by reducing PVL, is the most reliable means of reducing cervicovaginal shedding.


Subject(s)
Cervix Uteri/virology , HIV Infections/virology , HIV-1/isolation & purification , Vagina/virology , Viral Load , Virus Shedding , Adult , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , Cohort Studies , Female , HIV Infections/drug therapy , Humans , Longitudinal Studies , Middle Aged , Plasma/virology , Prospective Studies
12.
Pediatr Infect Dis J ; 29(1): 65-7, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19884875

ABSTRACT

Coccidioides immitis causes a wide range of disease in humans. Fluconazole and itraconazole are effective treatments. Clinical evidence suggests that itraconazole is equivalent or superior to fluconazole in treating osteoarticular infections in rates of cure and recurrence. We report 2 cases of coccidioidomycosis involving bone in children successfully treated with itraconazole oral solution. Itraconazole oral solution is effective in treating nonmeningeal coccidioidomycosis in children, particularly skeletal disease, and infections that are refractory to fluconazole.


Subject(s)
Antifungal Agents/therapeutic use , Coccidioides/isolation & purification , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Itraconazole/therapeutic use , Administration, Oral , Antifungal Agents/administration & dosage , Child , Child, Preschool , Coccidioides/drug effects , Coccidioidomycosis/microbiology , Female , Humans , Itraconazole/administration & dosage , Male , Osteomyelitis/drug therapy , Osteomyelitis/microbiology , Treatment Outcome
15.
J Infect Dis ; 197(6): 836-45, 2008 Mar 15.
Article in English | MEDLINE | ID: mdl-18279073

ABSTRACT

BACKGROUND: Intravenous ganciclovir administered for 6 weeks improves hearing outcomes in infants with symptomatic congenital cytomegalovirus (CMV) disease involving the central nervous system. METHODS: Twenty-four subjects received antiviral therapy for 6 weeks. Serial pharmacokinetic assessments were performed after administration of valganciclovir oral solution and of intravenous ganciclovir. RESULTS: On the basis of a previous pharmacokinetic study of the use of intravenous ganciclovir in this population, a target AUC12 (area under the concentration-time curve over a 12-h period) of 27 mg x h/L was defined. The median dose of oral valganciclovir administered in the present trial was 16 mg/kg, which produced a geometric mean AUC12 of 27.4 mg x h/L. The bioavailability of valganciclovir was 41.1%. Of the 18 subjects who had detectable CMV in whole blood at baseline or during therapy, 11 had <4 log viral DNA copies/mL at baseline, and 7 had > or =4 log viral DNA copies/mL at baseline; subjects who started the study with the higher viral burden experienced greater decreases in viral load but did not clear virus during the 42-day course of therapy. Neutropenia of grade 3 or 4 developed in 38% of subjects. CONCLUSIONS: In neonates with symptomatic congenital CMV disease, valganciclovir oral solution provides plasma concentrations of ganciclovir comparable to those achieved with administration of intravenous ganciclovir. The results of the present study cannot be extrapolated to extemporaneously compounded liquid formulations of valganciclovir.


Subject(s)
Cytomegalovirus Infections/drug therapy , Cytomegalovirus/isolation & purification , Ganciclovir/analogs & derivatives , Administration, Oral , Area Under Curve , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/virology , Drug Administration Schedule , Female , Ganciclovir/adverse effects , Ganciclovir/blood , Ganciclovir/pharmacokinetics , Ganciclovir/pharmacology , Humans , Infant, Newborn , Male , Valganciclovir , Viral Load
16.
Antimicrob Agents Chemother ; 49(1): 336-41, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15616313

ABSTRACT

A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease, in 20 HIV-infected children 4 to 12 years of age. The doses of amprenavir evaluated, 5, 10, 15, and 20 mg/kg of body weight, were comparable to those evaluated in adult phase I and II studies. The most common clinical adverse event associated with amprenavir, administered as soft gelatin capsules, was nausea. Amprenavir was rapidly absorbed, with a mean time to maximum concentration (T(max)) occurring 0.95 to 1.58 h after dosing. The area under the concentration-time curve (AUC(0)(-->)(infinity)) was dose proportional, and the mean maximum plasma concentration (C(max)) increased linearly in a less than dose-proportional manner. Amprenavir was eliminated relatively slowly, with a mean terminal-phase half-life (t(1/2)) of 6.17 to 8.28 h. The t(1/2), apparent total clearance, and apparent volume of distribution during the elimination phase were dose independent. Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies.


Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors , Sulfonamides , Area Under Curve , Carbamates , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Furans , HIV Infections/virology , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacokinetics , HIV-1 , Humans , Male , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Sulfonamides/pharmacokinetics , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL